Clinical Trial

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Study acronym: MARITIME-OSA-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
Protocol Amendment History 6 changes
notable Trial sites expanded: 56 -> 60 locations 2026-06-13
notable Trial sites expanded: 53 -> 56 locations 2026-05-23
notable Trial sites expanded: 47 -> 51 locations 2026-05-06
notable Trial sites expanded: 37 -> 43 locations 2026-04-10
notable Trial sites expanded: 33 -> 37 locations 2026-04-03
notable Trial sites expanded: 28 -> 33 locations 2026-03-31
Trial Details
NCT Number NCT07225686
Lead Sponsor Amgen
Conditions Obesity, Obstructive Sleep Apnea
Enrollment 250 participants
Start Date 2025-12-19
Primary Completion 2027-09-29 (estimated)
Study Completion 2028-09-13 (estimated)
Updated on ClinicalTrials.gov 2026-06-12